Literature DB >> 32115747

What risks should be permissible in controlled human infection model studies?

Ariella Binik1.   

Abstract

Controlled human infection model (CHIM) studies involve the intentional exposure of healthy research volunteers to infectious agents. These studies contribute to knowledge about the cause or development of disease and to the advancement of vaccine research. But they also raise ethical questions about the kinds of risks that should be permissible and whether limits should be imposed on research risks in CHIM studies. Two possible risk thresholds have been considered for CHIM studies. The first suggests constraining ethically permissible risks according to a minimal risk threshold and the second endorses a higher risk threshold that excludes irreversible or fatal infections. I argue that neither of these thresholds is persuasive and situate questions about risk thresholds in CHIM studies within a broader debate about permissible risks in research. I argue that risks in CHIM studies should be constrained according to limits on research risks that do not offer corresponding benefits in all studies rather than developing a unique risk threshold for CHIM studies. I then propose five recommendations for the ethical assessment of risk in CHIM studies.
© 2020 John Wiley & Sons Ltd.

Entities:  

Keywords:  challenge studies; clinical trials; controlled human infection model studies; ethics; research ethics; risk; risk threshold

Mesh:

Year:  2020        PMID: 32115747     DOI: 10.1111/bioe.12736

Source DB:  PubMed          Journal:  Bioethics        ISSN: 0269-9702            Impact factor:   1.898


  4 in total

1.  Ethical and practical considerations arising from community consultation on implementing controlled human infection studies using Schistosoma mansoni in Uganda.

Authors:  Moses Egesa; Agnes Ssali; Edward Tumwesige; Moses Kizza; Emmanuella Driciru; Fiona Luboga; Meta Roestenberg; Janet Seeley; Alison M Elliott
Journal:  Glob Bioeth       Date:  2022-07-04

2.  SARS-CoV-2 challenge studies: ethics and risk minimisation.

Authors:  Susan Bull; Euzebiusz Jamrozik; Ariella Binik; Michael J Parker
Journal:  J Med Ethics       Date:  2020-09-25       Impact factor: 2.903

3.  Why continuing uncertainties are no reason to postpone challenge trials for coronavirus vaccines.

Authors:  Robert Steel; Lara Buchak; Nir Eyal
Journal:  J Med Ethics       Date:  2020-07-13       Impact factor: 2.903

4.  Justifying the risks of COVID-19 challenge trials: The analogy with organ donation.

Authors:  Athmeya Jayaram; Jacob Sparks; Daniel Callies
Journal:  Bioethics       Date:  2021-06-27       Impact factor: 2.512

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.